According to filings with the U.S. Securities and Exchange Commission, Window Therapeutics is raising $7,550,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Chih-Kao Hu played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Window Therapeutics
Window Therapeutics is committed to discovering and developing transformational therapeutics to address critical unmet patient needs in cancer and other life-threatening diseases. Founded and based in Boston, MA, Window Therapeutics began operations in 2021. The company’s core Brush-Analogue Conjugate (BAC) technology is based on over ten years of progressive research and development from the laboratory of Dr. Jeremiah Johnson, Professor of Chemistry, Massachusetts Institute of Technology (MIT). By continually advancing and applying leading-edge research in the fields of molecular chemistry and biology, Window Therapeutics technologies can ‘power’ the development of breakthrough therapies, accelerate their progression to the clinic, and improve the lives of patients worldwide. Window Therapeutics combines the biological, chemistry, pharmaceutical, and medical expertise of global leaders to overcome the most fundamental barriers to effective cancer therapies.

To learn more about Window Therapeutics, visit http://www.windowtx.com/

Contact:
Chih-Kao Hu, Chief Executive Officer
617-287-5791

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.